Topical Medications for Atopic Dermatitis and Effects on Increasing Lymphoma Risks

Area of Science:

• Dermatology
• Immunology
• Oncology

Background:

• Atopic dermatitis is a relapsing, pruritic skin condition.
• Topical corticosteroids, a common treatment, have side effects like skin atrophy.
• Topical calcineurin inhibitors (TCIs) emerged as alternatives for severe cases, initially with no known long-term risks.

Purpose of the Study:

• To review existing studies investigating a potential association between topical calcineurin inhibitor use and lymphoma.
• To address the debate surrounding the immunosuppressive effects of TCIs and their link to skin cancers.

Main Methods:

• Systematic review of multiple studies.
• Analysis of data on TCI usage in patients with atopic dermatitis.
• Evaluation of lymphoma incidence in relation to TCI treatment.

Main Results:

• Systemic absorption of TCIs is minimal but increases with body surface area treated.
• Distinguishing between lymphoma risk from severe atopic dermatitis versus TCI treatment is challenging.
• The FDA issued a black box warning, classifying TCIs as second-line treatments due to inconclusive evidence.

Conclusions:

• The link between topical calcineurin inhibitors and lymphoma remains inconclusive.
• Further research is needed to clarify the safety profile of long-term TCI use.
• Current evidence does not definitively establish TCIs as a cause of lymphoma in atopic dermatitis patients.